Bristol-Myers Squibb has selected Kinaxo to support a number of its drug discovery programmes.

Under the agreement, Kinaxo will use its chemical proteomics technologies to deconvolute molecular targets of compounds currently being researched at Bristol-Myers Squibb.

The partnership will enable the companies to make informed decisions at various levels of drug discovery process, such as selecting the proper compound for clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData